Skip to content

Evaluation of the Efficacy and Safety of Ayurvedic oral medications in the management of Medoroga Adiposopathy and Body Weight

A Ten Arm, Randomized, Single blind, Active-Controlled, Clinical Study to Evaluate the Efficacy and Safety of Ayurvedic oral medications in the management of Medoroga Adiposopathy and Body Weight - RSCCAM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032347
Enrollment
360
Registered
2021-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: (Subjects will be randomized to one of the ten groups as per computer generated randomization list after screening. All the Subjects in all the Groups will be advised to take oral medic

Sponsors

National Innovation Foundation NIF
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with LDL-C >= 130 at the time of screening, Subjects with BMI >=23, Subjects willing to follow the procedures as per the study protocol and voluntarily give written informed consent

Exclusion criteria

Exclusion criteria: Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II, Subjects who have Diet with excess cholesterol, saturated fat or calories, Subjects with uncontrolled Hypothyroidism or Hyperthyroidism, Known cases of Severe/Chronic Hepatic or Renal disease, Known subject of any active malignancy, Subjects giving the history of significant cardiovascular event < 12 weeks prior to randomization, Known case of Anorexia Nervosa or Bulimia nervosa, Chronic alcoholics / Alcohol Abuse, Subjects ECG demonstrating any signs of uncontrolled arrhythmia or acute ischemia, Subjects X-ray chest showing any active lesion of tuberculosis, Subjects having known chronic, contagious infectious diseases, such as active tuberculosis Hepatitis B or C, or HIV, Subjects using any other investigational drug within 1 month prior to recruitment, Known hypersensitivity to any of the ingredients used in study drug, Pregnant and Lactating females, Subjects currently participating in any other clinical study, Any other medical or surgical condition considered unsuitable for subject participation in the study as per Investigatorâ??s judgment.

Design outcomes

Secondary

MeasureTime frame
change in TG, HDL,TC,EQ-5D, lipid profile, overall efficacy, safety assesmentTimepoint: 6 weeks, 12 weeks

Primary

MeasureTime frame
Change in LDL-C level at the end of study (12 weeks), Change in body weight at the end of study (12 weeks) Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Pawan kumar Godatwar

National Institute of Ayurveda (Deemed To Be University)

Pgodatwar@gmail.com9314502834

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026